Category: Vendor Spotlight

If there is a dental AI company that has most aggressively pursued the provider market — and specifically the DSO segment — it is Pearl. Based in Los Angeles, Pearl has positioned itself as the go-to AI platform for dental practices seeking real-time diagnostic assistance and practice analytics. With FDA-cleared products deployed across thousands of dental offices, partnerships with some of the largest DSOs in the country, and a product suite that extends well beyond basic radiograph analysis, Pearl has become a defining company in the dental AI landscape.

Company Background and Leadership

Pearl was founded in 2019 by Ophir Tanz, a serial entrepreneur who previously founded GumGum, a computer vision and contextual intelligence company. Tanz brought his expertise in applying computer vision to large-scale commercial problems into the dental space, recognizing that dental radiographs represented one of the largest untapped image datasets in healthcare. Under his leadership as CEO, Pearl has grown from a startup into one of the most widely deployed dental AI platforms in the United States.

The company has assembled a leadership team that combines dental clinical expertise with deep technology and business development backgrounds. Pearl’s clinical advisory board includes practicing dentists and dental specialists who inform the product development process — a factor that has contributed to the platform’s usability and clinical relevance.

Product Suite: Second Opinion and Practice Intelligence

Second Opinion: Real-Time Diagnostic AI

Pearl’s flagship clinical product is Second Opinion, an FDA-cleared AI system that analyzes dental radiographs in real time as they are captured in the operatory. The software automatically detects and annotates a wide range of dental conditions and features, including caries, periapical lesions, calculus, bone loss, existing restorations, crowns, and other findings. The annotations appear as color-coded overlays on the X-ray image, giving both the dentist and the patient a clear visual representation of the AI’s findings.

Second Opinion is designed as a clinical decision support tool — it assists but does not replace the dentist’s judgment. However, its real-time nature makes it particularly useful for patient communication and case acceptance. Multiple DSOs have reported that using Pearl’s visual overlays during patient consultations significantly improves patient understanding of recommended treatment, which in turn drives higher case acceptance rates.

The product integrates with widely used imaging systems and practice management software, and Pearl has invested significantly in making the deployment process as frictionless as possible — an important consideration for DSOs rolling out technology across hundreds of locations simultaneously.

Practice Intelligence: Analytics Beyond the Operatory

Pearl’s second major product line is Practice Intelligence, an analytics platform that aggregates diagnostic data across a dental organization to provide insights into clinical patterns, treatment trends, and quality metrics. For DSO leadership, Practice Intelligence offers a data-driven view into how individual practices and providers are performing relative to peers and organizational benchmarks.

The platform can surface insights such as undiagnosed conditions in patient populations, variation in diagnostic patterns across providers, and opportunities for improved patient care. This positions Practice Intelligence as both a quality assurance tool and a business intelligence tool — helping DSOs identify clinical improvement opportunities that also happen to have revenue implications.

Pearl’s combination of chairside diagnostic AI and enterprise-level practice analytics represents a full-stack approach to dental AI that few competitors have matched. The ability to capture data at the point of care and roll it up into organizational intelligence is a powerful value proposition for DSOs managing dozens or hundreds of locations.

FDA Clearances

Pearl has secured FDA 510(k) clearance for Second Opinion, making it one of the first dental AI platforms to receive formal regulatory authorization for clinical use. The company’s FDA clearance covers detection of multiple dental conditions from radiographic images. Pearl has publicly emphasized its FDA-cleared status as a key differentiator, and it is a factor that has been significant in winning DSO contracts where compliance and regulatory standing are evaluated during vendor selection.

The company has reported that its AI algorithms were trained on millions of dental images with annotations provided by dental professionals, and that its clinical validation studies have demonstrated performance comparable to or exceeding that of general dentists for specific detection tasks.

DSO Deployments and Scale

Pearl has secured several landmark DSO partnerships that underscore its reach in the organized dentistry market. PDS Health (formerly Pacific Dental Services), one of the largest dental support organizations in the United States with over 900 supported offices, deployed Pearl’s technology across its network — a deal that represented one of the largest AI rollouts in dental history. Coast Dental, another significant DSO, has also adopted Pearl’s platform.

These large-scale deployments have given Pearl a significant installed base and, critically, an enormous volume of real-world usage data that feeds back into model improvement. The company has reported that its AI has been used to analyze over 100 million dental images — a scale claim that, if accurate, would place it among the most widely used dental AI platforms globally.

• PDS Health: Enterprise-wide deployment across 900+ supported offices
• Coast Dental: Multi-location deployment of Second Opinion platform
• Thousands of Individual Practices: Growing adoption among independent dentists and smaller groups

Funding and Growth

Pearl has raised significant venture capital to fuel its growth. The company completed a $58 million Series B funding round in 2023, led by Left Lane Capital. This followed earlier rounds that brought the company’s total funding to over $80 million. The investment has supported Pearl’s aggressive DSO sales strategy, product development for Practice Intelligence, expansion of its engineering and clinical teams, and growing international ambitions.

The funding positions Pearl among the best-capitalized dental AI companies, alongside Overjet and VideaHealth. This level of investment suggests that Pearl’s backers see a large addressable market and believe the company can capture a significant share of it — but it also means Pearl will need to demonstrate strong revenue growth to justify its valuation over time.

Competitive Position: Strengths and Limitations

Pearl’s core strength lies in its laser focus on the provider side of the market and its demonstrated ability to deploy at DSO scale. The combination of chairside AI (Second Opinion) and enterprise analytics (Practice Intelligence) gives DSOs a more comprehensive platform than point solutions that only address diagnostic assistance. The company’s track record with major DSOs like PDS Health provides powerful social proof for other organizations evaluating dental AI.

That said, DSOs considering Pearl should weigh several factors. First, the dental AI market is becoming increasingly competitive, with companies like Overjet, VideaHealth, and others offering similar diagnostic capabilities. Differentiation increasingly hinges not just on detection accuracy but on integration depth, analytics, support quality, and pricing. Second, while Pearl’s Practice Intelligence platform is a strong differentiator, some DSOs may already have business intelligence tools in place and may need to evaluate how Pearl’s analytics complement or overlap with existing systems.

Third, unlike Overjet, Pearl does not have a significant presence on the insurance side of the market. Whether this is a strength (undivided focus on providers) or a limitation (missing a major revenue stream and data source) depends on one’s perspective. Some DSO leaders may prefer a vendor that is exclusively aligned with the provider side, free from potential conflicts of interest inherent in serving insurers simultaneously.

Looking Forward

Pearl enters the next phase of dental AI’s evolution from a position of strength. Its installed base across major DSOs, its FDA-cleared diagnostic platform, and its expanding Practice Intelligence analytics suite give it multiple vectors for growth. The company has signaled interest in international expansion and in broadening the range of clinical conditions its AI can detect.

For DSOs evaluating Pearl, the company presents a mature, well-funded, and widely deployed option with a clear focus on the provider market. The depth of its DSO relationships and its dual product strategy — combining real-time clinical AI with organizational analytics — make it a vendor worth serious consideration in any dental AI evaluation process. As with any technology investment, DSOs should assess integration requirements, pricing models, clinical validation data, and reference customers before making a commitment.

dsonews.ai is an independent publication. This vendor profile is provided for informational purposes and does not constitute an endorsement. DSOs should conduct their own due diligence before selecting any technology vendor.

In a dental industry historically slow to adopt new technology, Overjet has emerged as one of the most well-funded and strategically positioned AI companies operating at the intersection of clinical dentistry and insurance claims analysis. Founded in 2018 by a team of MIT researchers, the Boston-based company has built a dual-sided platform that serves both dental providers and payers — a business model that sets it apart from nearly every other competitor in the space.

Origins: From MIT Labs to Dental AI Pioneer

Overjet was co-founded by Dr. Wardah Inam, who serves as CEO, along with co-founders from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL). Dr. Inam, who holds a PhD from MIT, brought deep expertise in machine learning and computer vision to the dental vertical. The company’s founding thesis was straightforward but ambitious: dental X-rays contain enormous amounts of clinical information that human reviewers — whether dentists in the operatory or claims reviewers at insurance companies — can miss, interpret inconsistently, or process too slowly.

Headquartered in Boston, Massachusetts, Overjet has grown rapidly since its founding. The company has built a team that blends dental clinical expertise with deep technical talent in AI and computer vision — a combination that has proven essential for navigating both FDA regulatory requirements and the complex workflows of dental insurance claims processing.

The Dual Platform: Clinical AI and Insurance AI

What distinguishes Overjet from many dental AI competitors is its two-pronged approach. The company operates distinct but technologically related products for the clinical and insurance sides of the dental industry.

Clinical AI for Dental Practices and DSOs

On the clinical side, Overjet’s AI platform analyzes dental radiographs in real time, detecting and quantifying conditions including caries, bone loss, calculus, and other pathologies. The software overlays its findings directly onto X-ray images, providing dentists with a visual “second set of eyes” during diagnosis. For DSOs, this standardization of diagnostic interpretation across hundreds or thousands of providers is a significant value proposition — it helps reduce variability in treatment planning and supports quality assurance programs at scale.

Overjet’s clinical product integrates with major practice management systems and imaging software, allowing it to fit into existing dental workflows without requiring practices to overhaul their technology stack. The company has reported that its AI has analyzed tens of millions of dental images to date.

Insurance AI for Dental Payers

The insurance side of Overjet’s business is arguably what has driven its most prominent partnerships. Dental insurance companies process millions of claims annually, many of which include radiographic images that must be reviewed to verify that the proposed treatment matches the clinical evidence. Traditionally, this review has been performed manually by dental consultants — a slow, expensive, and inconsistent process.

Overjet’s insurance AI automates and augments this claims review process. The platform analyzes submitted radiographs, flags potential discrepancies between the clinical evidence and the proposed treatment, and helps insurers make faster, more consistent adjudication decisions. This has made the company a strategic partner for some of the largest dental benefits providers in the United States.

FDA Clearances and Regulatory Milestones

Overjet has secured multiple FDA clearances for its AI software, a critical differentiator in a market where many dental AI tools operate without formal regulatory approval. The company received FDA 510(k) clearance for its caries detection AI, and has also obtained clearance for its bone loss detection and measurement capabilities. These clearances position Overjet as one of a small handful of dental AI companies with formal regulatory authorization for clinical decision support — a factor that matters increasingly to DSOs and insurance companies evaluating AI vendors.

FDA clearance is not merely a regulatory checkbox — it signals that a company has submitted clinical validation data and passed scrutiny from federal regulators. For DSOs conducting due diligence on AI vendors, it remains one of the most tangible indicators of product maturity.

Major Customers and Partnerships

Overjet’s customer roster reads like a who’s who of dental insurance. Guardian Life, one of the largest mutual insurance companies in the United States, became an early and high-profile adopter of Overjet’s insurance AI platform. Delta Dental, the nation’s largest dental benefits provider, has also partnered with Overjet for claims analysis. These relationships have given Overjet access to massive volumes of dental imaging data and have validated its insurance AI product at enterprise scale.

On the clinical side, Overjet has expanded its presence among DSOs and group practices, though the company has historically been more publicly associated with its insurance partnerships. The dual positioning creates an interesting dynamic: Overjet’s AI is used by insurers to scrutinize claims, while the same underlying technology is offered to providers to improve diagnostic accuracy. The company maintains that this creates alignment rather than conflict — better diagnoses on the provider side should lead to cleaner claims on the payer side.

Funding and Financial Trajectory

Overjet has been one of the most aggressively funded dental AI startups. The company raised a $27 million Series B round in 2022, led by General Catalyst with participation from Insight Partners. This followed earlier seed and Series A rounds that included backing from investors such as E14 Fund and Crosslink Capital. In 2023, the company raised a $53 million Series C round, bringing its total funding to over $85 million. This level of capitalization is exceptional in the dental AI space and reflects investor confidence in Overjet’s dual-market strategy.

• Seed and Early Rounds: Initial funding from E14 Fund and early-stage investors
• Series B (2022): $27 million led by General Catalyst with Insight Partners
• Series C (2023): $53 million, bringing total funding over $85 million
• Key Investors: General Catalyst, Insight Partners, the Partnership Fund for New York City

Strengths and Considerations

Overjet’s greatest strategic advantage is its dual positioning across both the payer and provider sides of the dental market. This gives the company multiple revenue streams, access to far more imaging data than a purely clinical-focused competitor, and deep relationships with the insurance entities that often drive technology adoption standards in dentistry.

However, this dual positioning also raises questions that DSOs should consider. Some providers have expressed concern about AI tools that serve both sides of the claims adjudication process, wondering whether the technology could be used to deny legitimate claims. Overjet has addressed this by emphasizing that its clinical AI is designed to support — not override — the treating dentist’s judgment, and that its insurance AI improves consistency rather than systematically reducing approvals.

Additionally, while Overjet’s insurance AI has been validated at enormous scale through its partnerships with Guardian and Delta Dental, its clinical AI adoption among DSOs — while growing — faces stiff competition from rivals like Pearl, VideaHealth, and others who have focused exclusively on the provider market.

The Road Ahead

Overjet appears well-positioned to remain a major force in dental AI. Its substantial funding war chest, marquee insurance partnerships, growing clinical footprint, and multiple FDA clearances create a formidable competitive position. The company has indicated plans to expand its AI capabilities to additional clinical conditions and imaging modalities, and to deepen its integrations with practice management systems widely used by DSOs.

For DSO executives evaluating AI partners, Overjet presents a compelling case: a well-capitalized company with regulatory clearances, proven technology at scale on the insurance side, and a clinical platform that benefits from data insights drawn from processing millions of claims. The key question for each organization is whether the dual payer-provider model is a strength or a complication — and the answer may depend on the DSO’s own relationship with the insurance companies Overjet serves.

dsonews.ai is an independent publication. This vendor profile is provided for informational purposes and does not constitute an endorsement. DSOs should conduct their own due diligence before selecting any technology vendor.